ABT · ABBOTT LABORATORIES

Back to holdings

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Close · 3M

+16.73%

Held by 2 AI ETFs

AIVL0.842%

as of Sep 3

LQAI0.190%

as of Sep 3

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals21

Win rate57% (12/21)

Avg buy return+0.65%

AIVLnow 0.842% of fund26 signals

AIVL · Weight decrease · 3d

weight 0.945% → 0.842% (-0.102 pp)·stock up 2.9% in the 30 days before

Sep 3·entry $108.79·now $108.33

-0.42%

since Sep 3

AIVL · Weight decrease · 2d

weight 0.945% → 0.863% (-0.082 pp)·stock up 4.8% in the 30 days before

Sep 2·entry $110.47·now $108.33

-1.94%

since Sep 2

AIVL · Weight decrease · 3d

weight 0.982% → 0.939% (-0.044 pp)·stock up 3.3% in the 30 days before

Aug 27·entry $111.59·now $108.33

-2.92%

since Aug 27

AIVL · Weight decrease · 2d

weight 0.982% → 0.955% (-0.028 pp)·stock up 6.4% in the 30 days before

Aug 26·entry $114.10·now $108.33

-5.06%

since Aug 26

AIVL · Accumulation · 5d

weight 0.923% → 0.978% (+0.055 pp)·stock up 11.1% in the 30 days before

Aug 25·entry $116.13·now $108.33Fresh

-6.72%

since Aug 25

AIVL · Accumulation · 5d

weight 0.926% → 0.983% (+0.057 pp)·stock up 13.2% in the 30 days before

Aug 24·entry $116.67·now $108.33Fresh

-7.15%

since Aug 24

AIVL · Accumulation · 5d

weight 0.930% → 0.983% (+0.053 pp)·stock up 15.8% in the 30 days before

Aug 21·entry $116.64·now $108.33Fresh

-7.12%

since Aug 21

AIVL · Accumulation · 5d

weight 0.922% → 0.963% (+0.040 pp)·stock up 13.5% in the 30 days before

Aug 20·entry $114.14·now $108.33Fresh

-5.09%

since Aug 20

AIVL · Accumulation · 5d

weight 0.911% → 0.959% (+0.048 pp)·stock up 14.8% in the 30 days before

Aug 19·entry $114.43·now $108.33Fresh

-5.33%

since Aug 19

AIVL · Accumulation · 5d

weight 0.902% → 0.945% (+0.043 pp)·stock up 10.8% in the 30 days before

Aug 18·entry $112.68·now $108.33Fresh

-3.86%

since Aug 18

AIVL · Weight decrease · 2d

weight 0.930% → 0.923% (-0.007 pp)·stock up 12.6% in the 30 days before

Aug 14·entry $111.25·now $108.33

-2.62%

since Aug 14

AIVL · Accumulation · 5d

weight 0.902% → 0.926% (+0.023 pp)·stock up 24.6% in the 30 days before

Aug 13·entry $111.27·now $108.33Fresh

-2.64%

since Aug 13

AIVL · Weight increase · 3d

weight 0.902% → 0.930% (+0.027 pp)·stock up 24.7% in the 30 days before

Aug 12·entry $110.91·now $108.33Fresh

-2.33%

since Aug 12

AIVL · Weight increase · 2d

weight 0.902% → 0.922% (+0.020 pp)·stock up 19.1% in the 30 days before

Aug 11·entry $109.72·now $108.33Fresh

-1.27%

since Aug 11

AIVL · Weight increase · 2d

weight 0.902% → 0.909% (+0.007 pp)·stock up 13.4% in the 30 days before

Aug 6·entry $107.96·now $108.33Fresh

+0.34%

since Aug 6

AIVL · Accumulation · 5d

weight 0.956% → 1.017% (+0.061 pp)·stock up 16.5% in the 30 days before

Jul 29·entry $108.00·now $108.33Fresh

+0.31%

since Jul 29

AIVL · Accumulation · 5d

weight 0.932% → 0.999% (+0.068 pp)·stock up 14.0% in the 30 days before

Jul 28·entry $107.27·now $108.33Fresh

+0.99%

since Jul 28

AIVL · Accumulation · 5d

stock up 13.9% in the 30 days before

Jul 24·entry $103.06·now $108.33Drifting

+5.11%

since Jul 24

AIVL · Accumulation · 5d

stock up 11.3% in the 30 days before

Jul 23·entry $100.75·now $108.33Drifting

+7.52%

since Jul 23

AIVL · Accumulation · 5d

stock up 14.5% in the 30 days before

Jul 22·entry $100.57·now $108.33Drifting

+7.72%

since Jul 22

AIVL · Weight increase · 4d

stock up 14.9% in the 30 days before

Jul 20·entry $101.66·now $108.33Drifting

+6.56%

since Jul 20

AIVL · Weight increase · 3d

stock up 11.1% in the 30 days before

Jul 17·entry $100.68·now $108.33Drifting

+7.60%

since Jul 17

AIVL · Weight increase · 2d

stock up 11.5% in the 30 days before

Jul 16·entry $98.83·now $108.33Drifting

+9.61%

since Jul 16

AIVL · Weight decrease · 4d

stock down 0.8% in the 30 days before

Jul 14·entry $88.96·now $108.33

+21.77%

since Jul 14

AIVL · Weight decrease · 3d

stock up 3.3% in the 30 days before

Jul 13·entry $92.11·now $108.33

+17.61%

since Jul 13

AIVL · Weight decrease · 2d

stock up 2.9% in the 30 days before

Jul 10·entry $93.93·now $108.33

+15.33%

since Jul 10

LQAInow 0.190% of fund1 signal

LQAI · New entry · 1d

weight 0 → 0.200% (new)·stock up 13.4% in the 30 days before

Aug 6·entry $107.96·now $108.33Fresh

+0.34%

since Aug 6

AIEQno longer held3 signals

AIEQ · Exit · 1d

weight 0.230% → 0 (exited)·stock up 14.7% in the 30 days before

Aug 2·entry $107.12·now $108.33

+1.13%

since Aug 2

AIEQ · Weight increase · 2d

weight 0.220% → 0.240% (+0.020 pp)·stock up 16.4% in the 30 days before

Jul 30·entry $105.61·now $108.33Drifting

+2.58%

since Jul 30

AIEQ · Weight increase · 2d

stock up 11.1% in the 30 days before

Jul 19·entry $101.66·now $108.33Drifting

+6.56%

since Jul 19

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of Aug 23

AI ETFs, particularly AIVL, have shown recent gradual accumulation of Abbott Laboratories shares, indicating a positive sentiment and increasing conviction in the stock. This contrasts with the Buffett-style framework's verdict of 'Fail,' which identifies concerns regarding the company's financial health based on available data and its current valuation failing to offer a sufficient margin of safety.

Circle of CompetenceAbbott Laboratories operates in diversified, yet generally predictable segments of healthcare, allowing for reasonable projection of cash flows over ten years.
Economic MoatAbbott benefits from strong brand recognition, high switching costs for integrated medical devices and diagnostic platforms, and intellectual property/regulatory barriers.
ManagementThe provided data does not offer sufficient information to assess management's candor, capital allocation discipline, or ownership stake.
Financial HealthThe provided ROE of 10.52% falls below the framework's requirement for a 10-year average ROE of at least 15%, and other critical financial details are unavailable for full assessment.
Margin of SafetyWith a PER of 35.52 and EV/EBITDA of 28.14, the company appears richly valued, offering no apparent defensible discount to intrinsic value or margin of safety.

Abbott Laboratories demonstrates a predictable business model and strong economic moats, satisfying the initial stages of this framework. However, the analysis is hindered by insufficient financial data to confirm adherence to key health benchmarks, and the company's current valuation multiples suggest a lack of margin of safety, leading to an overall 'Fail' verdict.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.